Compare Omnicom Group Inc. (OMC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs Sana Biotechnology Inc — how do they compare? Omnicom Group Inc. trades at $76.55 (market cap $20.97B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: Omnicom Group Inc. is far larger — about 25.1× Sana Biotechnology Inc's market cap, and Omnicom Group Inc. pays a 4.19% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and Sana Biotechnology Inc for 23 Days on average.
| OMC | SANA | |
|---|---|---|
Market Cap | $20.97B | $836.71M |
Volume | 2,092,899 | 4,507,444 |
Sector | Media | Health |
52-Week High | $88.94 | $5.92 |
52-Week Low | $67.27 | $2.68 |
Typical Hold Time | 63 Days | 23 Days |
Enterprise Value | $29.05B | $749.96M |
Dividend Yield | 4.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $76.32, up 1.94% on the day, with a bullish technical signal but mixed earnings history. The company reported a net loss of $54.5 million in 2025 despite revenue growth to $17.27 billion, with a high P/E ratio of 206.62 but attractive P/S of 0.86. Recent news highlights leadership in digital marketing and $3.3 billion in new H1 2026 billings, supporting positive sentiment.
Outlook is cautiously optimistic given analyst consensus price target of $100.50 (32% upside) and strong institutional interest, but risks include ad market volatility, high debt, and thin net margins. The stock offers value through a 4.2% dividend yield and post-merger synergies, though investors should monitor earnings consistency and macroeconomic pressures on advertising spend.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
